Blood test may predict lung cancer spread in early stages
NCT ID NCT00818558
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at whether a blood test called ISET can find circulating tumor cells in people with early-stage non-small cell lung cancer. Researchers checked blood samples from 256 patients before surgery to see if these cells were linked to cancer stage, type, and survival. The goal was to learn if this test could help predict recurrence or spread, not to treat the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors better predict lung cancer recurrence or spread using a simple blood test.
- What could go wrong
- This is an observational study, not a treatment trial. It may not lead to any direct benefit for patients, and results may not change current care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pr Paul HOFMAN
Nice, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?